

## NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Health Technology Appraisal

## Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma ID3795

## Provisional Stakeholder List

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> <li>• MorphoSys AG - partnered with Incyte Corp (tafasitamab)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• African Caribbean Leukaemia Trust</li> <li>• Anthony Nolan</li> <li>• Black Health Agency</li> <li>• Blood Cancer UK</li> <li>• Cancer Black Care</li> <li>• Cancer Equality</li> <li>• Cancer52</li> <li>• Chronic Lymphocytic Leukaemia Support Association</li> <li>• DKMS</li> <li>• Helen Rollason Cancer Charity</li> <li>• Leukaemia Cancer Society</li> <li>• Independent Cancer Patients Voice</li> <li>• Lymphoma Action</li> <li>• Macmillan Cancer Support</li> <li>• Maggie's Centres</li> <li>• Marie Curie</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> <li>• Tenovus Cancer Care</li> <li>• WMUK</li> </ul> <p><u>Professional groups</u></p> <ul style="list-style-type: none"> <li>• Association of Cancer Physicians</li> <li>• British Committee for Standards in Haematology</li> <li>• British Geriatrics Society</li> <li>• British Institute of Radiology</li> <li>• British Psychosocial Oncology Society</li> <li>• British Society for Haematology</li> <li>• Cancer Research UK</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• All Wales Therapeutics &amp; Toxicology Centre</li> <li>• Allied Health Professionals Federation</li> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Healthcare Improvement Scotland</li> <li>• Medicines and Healthcare Products Regulatory Agency</li> <li>• National Association of Primary Care</li> <li>• National Pharmacy Association</li> <li>• NHS Alliance</li> <li>• NHS Confederation</li> <li>• Scottish Medicines Consortium</li> <li>• Welsh Health Specialised Services Committee</li> </ul> <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> <li>• Accord Healthcare Ltd (bendamustine, bleomycin, etoposide, gemcitabine, mitoxantrone, oxaliplatin, prednisolone)</li> <li>• Advanz Pharma (dexamethasone, prednisolone)</li> <li>• Aspen (chlorambucil)</li> <li>• Baxter Healthcare Ltd (bendamustine, cyclophosphamide, mitoxantrone)</li> <li>• Cheplapharm Arzneimittel GmbH (etoposide)</li> <li>• Consilient Health (dexamethasone)</li> <li>• Dr Reddy's Laboratories UK Ltd (bendamustine)</li> <li>• Glenmark Pharmaceuticals Europe Ltd. (dexamethasone)</li> <li>• Hospira UK (gemcitabine, mitoxantrone, oxaliplatin, vincristine)</li> </ul>

Provisional stakeholder list for the technology appraisal of tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma ID3795. Issue date: August 2020

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> <li>• Royal college of Radiologists</li> <li>• Royal Pharmaceutical Society</li> <li>• Royal Society of Medicine</li> <li>• Society and college of Radiology</li> <li>• UK Clinical Pharmacy Association</li> <li>• UK Health Forum</li> <li>• UK Oncology Nursing Society</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health and Social Care</li> <li>• NHS Ipswich and East Suffolk CCG</li> <li>• NHS England</li> <li>• NHS Shropshire CCG</li> <li>• Welsh Government</li> </ul>	<ul style="list-style-type: none"> <li>• Kyowa Kirin Ltd. (bleomycin)</li> <li>• Medac UK (bendamustine, etoposide, lomustine, oxaliplatin)</li> <li>• Napp Pharmaceuticals Ltd (rituximab)</li> <li>• Pfizer Ltd (gemcitabine)</li> <li>• Ranbaxy (UK) Ltd, a Sun Pharmaceutical Company (gemcitabine, oxaliplatin)</li> <li>• Phoenix Labs (prednisolone)</li> <li>• Roche Products Ltd (polatuzumab, rituximab)</li> <li>• Rosemont (dexamethasone)</li> <li>• Sandoz Ltd (cyclophosphamide, oxaliplatin, rituximab)</li> <li>• Seacross pharmaceuticals (bendamustine, oxaliplatin)</li> <li>• Servier Laboratories (pixantrone)</li> <li>• Synchrony (dexamethasone)</li> <li>• Wockhardt (dexamethasone, prednisolone)</li> <li>• Zentiva (bendamustine, prednisolone)</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• Cochrane Haematological Malignancies Group</li> <li>• Genomics England</li> <li>• Institute of Cancer Research</li> <li>• Leuka</li> <li>• Leukaemia Busters</li> <li>• Lymphoma Research Trust</li> <li>• MRC Clinical Trials Unit</li> <li>• National Cancer Research Institute</li> <li>• National Cancer Research Network</li> <li>• National Institute for Health Research</li> </ul> <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> <li>• Public Health England</li> <li>• Public Health Wales</li> </ul>

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

***PTO FOR DEFINITIONS OF CONSULTees AND COMMENTATORS***

### Definitions:

#### Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement<sup>1</sup>, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

#### Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical specialists or patient experts.

---

<sup>1</sup> Non-company consultees are invited to submit statements relevant to the group they are representing.